8 results on '"Yee, Monica"'
Search Results
2. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).
- Author
-
Roth, Joshua A., Trivedi, Meghna S., Gray, Stacy W., Patrick, Donald L., Delaney, Debbie M., Watabayashi, Kate, Litwin, Paul, Shah, Parth, Crew, Katherine D., Yee, Monica, Redman, Mary W., Unger, Joseph M., Papadimitrakopoulou, Vassiliki, Johnson, Judy, Kelly, Karen, Gandara, David, Herbst, Roy S., Hershman, Dawn L., and Ramsey, Scott D.
- Subjects
LUNG cancer ,SEQUENCE analysis ,CONFIDENCE intervals ,INTERVIEWING ,PATIENTS' attitudes ,HEALTH literacy ,CANCER patients ,HEALTH attitudes ,GENOMICS ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMOR markers ,LOGISTIC regression analysis ,ODDS ratio ,DATA analysis software - Abstract
PURPOSE Biomarker-driven master protocols represent a new paradigm in oncology clinical trials, but their complex designs and wide-ranging genomic results returned can be difficult to communicate to participants. The objective of this pilot study was to evaluate patient knowledge and expectations related to return of genomic results in the Lung Cancer Master Protocol (Lung-MAP). METHODS Eligible participants with previously treated advanced non-small-cell lung cancer were recruited from patients enrolled in Lung-MAP. Participants completed a 38-item telephone survey ≥ 30 days from Lung-MAP consent. The survey assessed understanding about the benefits and risks of Lung-MAP participation and knowledge of the potential uses of somatic testing results returned. Descriptive statistics and odds ratios for associations between demographic factors and correct responses to survey items were assessed. RESULTS From August 1, 2017, to June 30, 2019, we recruited 207 participants with a median age of 67, 57.3% male, and 94.2% White. Most participants "strongly/somewhat agreed" with statements that they "received enough information to understand" Lung-MAP benefits (82.6%) and risks (69.5%). In items asking about potential uses of Lung-MAP genomic results, 87.0%correctly indicated that the results help to select cancer treatment, but < 20% correctly indicated that the results are not used to confirm cancer diagnosis, would not reveal risk of developing diseases besides cancer, and would not indicate if family members had increased cancer risk. There were no associations between sociodemographic factors and proportions providing correct responses. CONCLUSION In a large National Clinical Trials Network biomarker-driven master protocol, most participants demonstrated incorrect knowledge and expectations about the uses of genomic results provided in the study despite most indicating that they had enough information to understand benefits and risks. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).
- Author
-
Kryscio, Richard J., Abner, Erin L., Caban-Holt, Allison, Lovell, Mark, Goodman, Phyllis, Darke, Amy K., Yee, Monica, Crowley, John, and Schmitt, Frederick A.
- Published
- 2017
- Full Text
- View/download PDF
4. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.
- Author
-
Goodman, Phyllis J., Tangen, Catherine M., Darke, Amy K., Arnold, Kathryn B., Hartline, JoAnn, Yee, Monica, Anderson, Karen, Caban-Holt, Allison, Christen, William G., Cassano, Patricia A., Lance, Peter, Klein, Eric A., Crowley, John J., Minasian, Lori M., and Meyskens, Frank L.
- Subjects
CANCER prevention ,VITAMIN E ,SELENIUM ,ANTIOXIDANTS ,CLINICAL trials ,ANTINEOPLASTIC agents ,BIOLOGICAL assay ,COMPARATIVE studies ,DATABASES ,EXPERIMENTAL design ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,PROSTATE tumors ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,RETROSPECTIVE studies ,DIAGNOSIS ,PREVENTION - Abstract
Background: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind, placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial's development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants. To capitalize on the knowledge gained from following a large cohort of healthy, aging males on the effects of selenium and/or vitamin E, ancillary studies with other disease endpoints were solicited.Methods: Four ancillary studies were added. Each drew from the same population but had independent objectives and an endpoint other than prostate cancer. These studies fell into two categories: those prospectively enrolling and following participants (studies of Alzheimer's disease and respiratory function) and those requiring a retrospective medical record review after a reported event (cataracts/age-related macular degeneration and colorectal screening). An examination of the challenges and opportunities of adding ancillary studies is provided. The impact of the ancillary studies on adherence to SELECT was evaluated using a Cox proportional hazards model.Results: While the addition of ancillary studies appears to have improved participant adherence to the primary trial, this did not come without added complexity. Activation of the ancillary studies happened after the SELECT randomizations had begun resulting in accrual problems to some of the studies. Study site participation in the ancillary trials varied greatly and depended on the interest of the study site principal investigator. Procedures for each were integrated into the primary trial and all monitoring was done by the SELECT Data and Safety Monitoring Committee. The impact of the early closure of the primary trial was different for each of the ancillary trials.Conclusions: The ancillary studies allowed study sites to broaden the research opportunities for their participants. Their implementation was efficient because of the established infrastructure of the primary trial. Implementation of these ancillary trials took substantial planning and coordination but enriched the overall primary trial.Trial Registration: NCT00006392-S0000 : Selenium and Vitamin E in Preventing Prostate Cancer (SELECT) (4 October 2000). NCT00780689-S0000A : Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) (25 June 2002). NCT00784225-S0000B : Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000 (SEE) (31 October 2008). NCT00706121-S0000D : Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 (ACP) (26 June 2008). NCT00063453-S0000C : Vitamin E and/or Selenium in Preventing Loss of Lung Function in Older Men Enrolled on SELECT Clinical Trial SWOG-S0000 (26 June 2003). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
5. Moving a randomized clinical trial into an observational cohort.
- Author
-
Goodman, Phyllis J, Hartline, Jo Ann, Tangen, Catherine M, Crowley, John J, Minasian, Lori M, Klein, Eric A, Cook, Elise D, Darke, Amy K, Arnold, Kathryn B, Anderson, Karen, Yee, Monica, Meyskens, Frank L, and Baker, Laurence H
- Subjects
SCIENTIFIC observation ,PROSTATE tumors ,RANDOMIZED controlled trials ,RESEARCH funding ,TRANSITIONAL programs (Education) ,DESCRIPTIVE statistics ,PREVENTION - Published
- 2013
- Full Text
- View/download PDF
6. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812.
- Author
-
McGuinness JE, Anderson GL, Mutasa S, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser ML, Goodman GE, Brown PH, Ha R, and Crew KD
- Abstract
Deep learning-based mammographic evaluations could noninvasively assess response to breast cancer (BC) chemoprevention. We evaluated change in a convolutional neural network (CNN)-based BC risk model applied to mammograms among women enrolled in SWOG S0812, which randomized 208 premenopausal high-risk women to receive oral vitamin D3 20,000IU weekly or placebo for 12 months. We applied the CNN model to mammograms collected at baseline (n = 109), 12 months (n = 97) and 24 months (n = 67), and compared changes in CNN risk score between treatment groups. Change in CNN score was neither significantly different between vitamin D and placebo groups at 12 months (0.005 vs. 0.002, p = 0.875) nor at 24 months (0.020 vs. 0.001, p = 0.563). The findings are consistent with the primary analysis of S0812, which did not demonstrate significant changes in MD with vitamin D supplementation compared to placebo. There is an ongoing need to evaluate biomarkers of response to novel BC chemopreventive agents., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
7. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).
- Author
-
Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, and Brown PH
- Subjects
- Adult, Breast Neoplasms blood, Breast Neoplasms pathology, Carcinoma, Ductal, Breast blood, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular blood, Carcinoma, Lobular pathology, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperplasia blood, Hyperplasia drug therapy, Hyperplasia pathology, Insulin-Like Growth Factor Binding Protein 3 blood, Insulin-Like Growth Factor I analysis, Middle Aged, Prognosis, Risk Factors, Vitamin D administration & dosage, Biomarkers blood, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Lobular drug therapy, Dietary Supplements, Premenopause, Vitamin D analogs & derivatives
- Abstract
Observational studies have reported an inverse association between vitamin D intake and breast cancer risk. We examined whether vitamin D supplementation in high-risk premenopausal women reduces mammographic density (MD), an established breast cancer risk factor. We conducted a multicenter randomized double-blind placebo-controlled trial in premenopausal women at high risk for breast cancer [5-year risk ≥ 1.67%, lifetime risk ≥ 20%, lobular carcinoma in situ , prior stage 0-II breast cancer, hereditary breast cancer syndrome, or high MD (heterogeneously/extremely dense)], with a baseline serum 25-hydroxyvitamin D [25(OH)D] ≤ 32 ng/mL. Participants were randomized to 12 months of vitamin D3 20,000 IU/week or matching placebo. The primary endpoint was change in MD from baseline to 12 months using the Cumulus technique. Secondary endpoints included serial blood biomarkers [25(OH)D, 1,25-dihydroxyvitamin D (1,25(OH)D), insulin-like growth factor (IGF)-1, IGF-binding protein-3] and MD change at 24 months. Among 208 women randomized, median age was 44.6 years, 84% were white, 33% had baseline 25(OH)D < 20 ng/mL, and 78% had high baseline MD. Comparing the active and placebo groups at 12 months, MD changes were small and did not significantly differ. Mean MD changes at 12 and 24 months were -0.3% and -1.2%, respectively, in the active arm and +1.5% and +1.6% with placebo ( P > 0.05). We observed a mean change in serum 25(OH)D of +18.9 versus +2.8 ng/mL ( P < 0.01) and IGF-1 of -9.8 versus -1.8 ng/mL ( P = 0.28), respectively. At 12 months, MD was positively correlated with serum IGF-1 and IGF-1/IGFBP-3 ( P < 0.01). This trial does not support the use of vitamin D supplementation for breast cancer risk reduction., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
8. Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention.
- Author
-
Lance P, Alberts DS, Thompson PA, Fales L, Wang F, San Jose J, Jacobs ET, Goodman PJ, Darke AK, Yee M, Minasian L, Thompson IM, and Roe DJ
- Subjects
- Adenoma diagnostic imaging, Adenoma epidemiology, Adenoma pathology, Aged, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms epidemiology, Colorectal Neoplasms pathology, Dietary Supplements, Humans, Incidence, Male, Middle Aged, Prostatic Neoplasms epidemiology, Risk Factors, Sigmoidoscopy, Adenoma prevention & control, Antioxidants administration & dosage, Colorectal Neoplasms prevention & control, Prostatic Neoplasms prevention & control, Selenomethionine administration & dosage, alpha-Tocopherol administration & dosage
- Abstract
Selenium and vitamin E micronutrients have been advocated for the prevention of colorectal cancer. Colorectal adenoma occurrence was used as a surrogate for colorectal cancer in an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer prevention. The primary objective was to measure the effect of selenium (as selenomethionine) on colorectal adenomas occurrence, with the effect of vitamin E (as α-tocopherol) supplementation on colorectal adenoma occurrence considered as a secondary objective. Participants who underwent lower endoscopy while in SELECT were identified from a subgroup of the 35,533 men randomized in the trial. Adenoma occurrence was ascertained from the endoscopy and pathology reports for these procedures. Relative Risk (RR) estimates and 95% confidence intervals (CI) of adenoma occurrence were generated comparing those randomized to selenium versus placebo and to vitamin E versus placebo based on the full factorial design. Evaluable endoscopy information was obtained for 6,546 participants, of whom 2,286 had 1+ adenomas. Apart from 21 flexible sigmoidoscopies, all the procedures yielding adenomas were colonoscopies. Adenomas occurred in 34.2% and 35.7%, respectively, of participants whose intervention included or did not include selenium. Compared with placebo, the RR for adenoma occurrence in participants randomized to selenium was 0.96 (95% CI, 0.90-1.02; P = 0.194). Vitamin E did not affect adenoma occurrence compared with placebo (RR = 1.03; 95% CI, 0.96-1.10; P = 0.38). Neither selenium nor vitamin E supplementation can be recommended for colorectal adenoma prevention. Cancer Prev Res; 10(1); 45-54. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.